Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Timber Pharmaceuticals Inc (TMBR)

Timber Pharmaceuticals Inc (TMBR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ESTE, PR, TMBR PR Newswire - Mon Aug 21, 2023

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

PR : 20.15 (-0.64%)
CTG : 10.50 (+0.10%)
TMBR : 0.3426 (+0.74%)
ESTE : 21.17 (+0.47%)
Timber Pharmaceuticals’ (NYSE American: TMBR) Phase 3 ASCEND Study for TMB-001: A Leap Forward in Congenital Ichthyosis Treatment Spotlight Growth - Mon Jun 5, 2023

Significant Progress in Timber Pharmaceuticals' Phase 3 ASCEND Study Timber Pharmaceuticals (NYSE American: TMBR), a clinical-stage biopharmaceutical company specializing in

TMBR : 0.3426 (+0.74%)
Timber Pharmaceuticals (NYSE American: TMBR) Granted Orphan Drug Designation in Europe for TMB-001 Spotlight Growth - Fri Feb 24, 2023

Timber Pharmaceuticals, Inc. (NYSE American: TMBR) is engaged as a clinical-stage biopharmaceutical company, which is focused on the development and

TMBR : 0.3426 (+0.74%)

Barchart Exclusives

1 Million Reasons to Buy SoFi Stock Now Barchart - Sat Aug 8, 2:30PM CDT
SoFi Plus hit 200K paid members in one quarter. CEO Anthony Noto wants 1 million within a year. Here's why that target matters for SOFI stock. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.